340B Rebate Model RFI: What FQHCs Need to Know and Submit Before April 20

Executive Summary

HRSA’s February 2026 Request for Information on a 340B Rebate Model Pilot Program would upend how covered entities receive drug discounts. Under the proposed model, FQHCs would pay full Wholesale Acquisition Cost (WAC) upfront, then recover the 340B discount via post-dispense rebate claim. Rebates are subject to a 45-day submission deadline. This creates a denial risk framework analogous to timely filing rules. A federal court vacated the original pilot in February 2026, but HRSA’s RFI signals intent to reconstitute the program through proper rulemaking — potentially expanding scope to drugs selected under the IRA Medicare Drug Price Negotiation Program. FQHCs have until April 20, 2026 to submit comments shaping the operational safeguards built into any reconstituted model. Revenue cycle, pharmacy, and finance leadership should act now.

Background / Regulatory Context

The 340B Drug Pricing Program — authorized under Section 340B of the Public Health Service Act (42 U.S.C. § 256b) — has delivered upfront drug discounts to covered entities since 1992. Manufacturers charge at or below the HRSA ceiling price at the point of purchase. The discount is immediate. No claims are filed. No reimbursement is awaited. In 2024, $81.4 billion in drugs moved through the 340B program under this model.

In August 2025, HRSA proposed a fundamental redesign. HRSA published an Application Notice (Federal Register Document 2025-14619, August 1, 2025) establishing a Rebate Model Pilot Program for select drugs. Under the new model, manufacturers would charge covered entities full WAC at purchase. Covered entities would then submit post-dispense rebate claims to recover the WAC-to-ceiling-price spread.

The pilot never launched. On December 29, 2025, the U.S. District Court for the District of Maine issued a preliminary injunction in American Hospital Association et al. v. Kennedy, No. 2:25-cv-00600-LEW. On February 10, 2026, the court vacated the Application Notice entirely — finding HRSA violated the Administrative Procedure Act. The court found that HRSA failed to weigh 30 years of covered entity reliance on upfront discounts and failed to address the administrative and cash-flow burden on safety-net providers. The government dropped its appeal on January 20, 2026.

HRSA responded with a Request for Information published February 17, 2026 (Federal Register, Vol. 91, No. 31, Document No. 2026-03042). The RFI asks stakeholders to weigh in on how a reconstituted pilot should be designed. A February 26, 2026 extension notice (Document 2026-03838) pushed the comment deadline to April 20, 2026 and signaled HRSA may expand pilot scope to cover drugs selected under the IRA’s Medicare Drug Price Negotiation Program — significantly broadening financial exposure beyond the original nine drugs.

The 340B program supported $81.4 billion in drug purchases in 2024. Thousands of covered entities rely on 340B savings to cross-subsidize uncompensated care and mission-driven services.

The Denial Mechanism

The rebate model reframes 340B discount recovery as a claims-like submission process. With that reframing comes claims-like denial risk.

Under the current upfront discount model, there is no “claim” to deny. The manufacturer delivers the drug at or below the ceiling price. The discount is locked in at purchase. Under the rebate model, the FQHC pays full WAC upfront — potentially hundreds of dollars per unit above the 340B price — and then submits a rebate claim within 45 days of the date of dispense.

If the claim is incomplete, submitted late, or rejected by the manufacturer, the FQHC forfeits that rebate. The unit was dispensed at a loss relative to 340B ceiling pricing. There is no secondary appeal pathway established in final rule. The working capital absorbed at WAC pricing is not recovered.

This denial mechanism mirrors timely filing in traditional claims billing — with one critical distinction. Payers carry contractual and regulatory obligations to process and pay clean claims within defined windows. Under the RFI model, the proposed 10-calendar-day manufacturer payment deadline has not been codified. Until a final rule establishes enforceable timelines, the FQHC bears full exposure for payment delays, manufacturer disputes, and system failures.

Top Denial Triggers

Missed 45-day submission window. Rebate claims must be submitted within 45 days of the date of dispense. This is a hard deadline with no established grace period. Any claim submitted after the window is ineligible for rebate recovery — the functional equivalent of a timely filing denial.
Incomplete claim data. Each rebate submission requires 12 to 14 data fields: NDC-11, quantity dispensed, 340B entity ID, BIN/PCN for pharmacy claims, date of service, prescriber ID, and additional fields. A single missing or inaccurate field can trigger rejection.
EHR-to-pharmacy system gaps. Integration failures between the EHR, pharmacy dispensing system, and 340B eligibility platform are the primary driver of incomplete submissions. If dispensing data does not flow into the rebate submission system with full field capture, claims generate with errors before staff review.
Dual-workflow routing errors. The rebate model applies only to select drugs; all other 340B drugs continue under the upfront discount model. Staff routing a rebate-model drug through the upfront discount channel — or vice versa — will produce revenue leakage or duplicate discount exposure.
340B eligibility failures at point of dispense. Under the rebate model, the FQHC pays full WAC upfront before eligibility is fully confirmed. If a dispense is later determined not to meet 340B qualification requirements, the rebate claim cannot be submitted — and the full WAC cost was already absorbed.
Uncoded manufacturer dispute exposure. Manufacturers have proposed authority to dispute rebate claims. The 10-day payment timeline is not yet codified. If a manufacturer disputes a claim after the FQHC absorbed full WAC cost, recovery depends on a resolution process not yet defined in final rule.
Scope expansion outpacing system capacity. The vacated pilot covered nine to ten drugs from eight manufacturers. HRSA’s extension notice signals potential expansion to drugs selected under the IRA Medicare Drug Price Negotiation Program. If scope expands, submission volume multiplies and entities sized for the original pilot may be structurally underprepared.

Prevention Strategies

Model your drug-level cash flow exposure now. Identify which drugs in your formulary appeared in the vacated pilot — including Eliquis, Enbrel, Entresto, Farxiga, Imbruvica, Januvia, Jardiance, NovoLog/Fiasp, Stelara, and Xarelto — and any IRA-negotiated drugs that may be added. Calculate monthly dispense volume multiplied by the WAC-to-ceiling spread for each drug. This data anchors both your comment submission and your operational readiness plan.
Audit your EHR-to-pharmacy data pipeline. Pull a sample of current 340B dispense records and validate that all 12 to 14 required rebate claim fields are captured automatically and accurately. Identify any fields requiring manual entry and build automation workflows before any pilot launch.
Set a 30-day internal submission target. Build a 15-day cushion into your timely filing controls. If the manufacturer deadline is 45 days from dispense, your internal workflow should target claim generation and review at day 30. Apply the same escalation logic used for aging A/R.
Assign a single owner for rebate submission tracking. The rebate function spans pharmacy, billing, and finance. Designate one accountable owner — analogous to your denial management coordinator for traditional claims. Establish daily or weekly queue reviews before any pilot goes live.
Evaluate third-party rebate intermediary capabilities. Third-party intermediaries such as Beacon can support rebate claim preparation and submission. Assess their data capture requirements, submission track record, and dispute resolution support. Do not assume third-party infrastructure eliminates internal data quality obligations.
Use NACHC’s tools to build your comment submission. NACHC has developed financial/administrative burden calculators and template comment letters for health centers participating in the April 20 comment process. Use the calculators to quantify local cash-flow exposure. Customize the template with your organization’s operational data before submitting.
Build separate tracking systems for each workflow. Do not route rebate-model drugs and upfront-discount drugs through a single tracking queue. Establish separate reports, escalation protocols, and audit trails from day one. Test separation before any pilot launch.

FQHC Note

FQHCs occupy a uniquely vulnerable position in any rebate model scenario. Section 340B savings directly fund sliding-fee services and cross-subsidize uncompensated care required by Health Center Program grant conditions under Section 330 of the Public Health Service Act. A cash flow gap created by the WAC-to-rebate timing — even a 10 to 30-day delay — affects operating liquidity at organizations that operate on thin margins and rely on federal grant funding cycles.

The court’s reasoning in AHA v. Kennedy provides a direct evidentiary framework for FQHC comment submissions. The court found that HRSA failed to weigh covered entity reliance interests and failed to address the administrative burden on safety-net providers. FQHCs should document and quantify their local financial exposure — working capital gap per drug per month at WAC — and submit that data as part of their RFI response. This evidence base was precisely what the court identified as missing from HRSA’s original analysis.

H.R. 7391, the Community Health Center Drug Pricing Protection Act, was introduced on February 5, 2026 with bipartisan sponsorship (Reps. Auchincloss and Bergman) and 35 cosponsors. The bill has been referred to the House Committee on Energy and Commerce with no markup or floor action to date. It would amend Title III of the Public Health Service Act to prohibit manufacturers from charging FQHCs more than the 340B ceiling price at point of purchase — a statutory exemption from any rebate model. NACHC and PACHC are urging health centers to contact congressional representatives to build support.

Operational Impact: Billing, Pharmacy, and Finance

Billing: Implement a parallel rebate claim tracking queue with timely filing escalation protocols identical to traditional claims management. Rebate submission is not a pharmacy-only function — RCM staff should own the filing deadline and denial follow-up workflow.

Pharmacy: Validate that dispensing system data fields map completely to rebate claim submission requirements. Establish drug-level flagging to distinguish rebate-model drugs from upfront-discount drugs at the point of dispense.

Finance: Model monthly cash flow impact for each rebate-model drug at full WAC pricing. Calculate the working capital reserve required to cover the WAC-to-rebate gap at current dispense volumes. Build scope expansion scenarios — including potential IRA-negotiated drug expansion — into financial contingency planning.

Action Checklist: Before April 20, 2026

Federal Register Document No.: 2026-03042 | HHS Docket No. HRSA-2026-03042
Comment Deadline: April 20, 2026

Submit comments to HRSA at regulations.gov, Docket No. HRSA-2026-03042, by April 20, 2026.
Use NACHC tools — download the financial burden calculator and template comment letter at nachc.org.
Quantify your exposure — calculate the WAC-to-ceiling spread for each pilot-scope drug multiplied by monthly dispense volume.
Address all seven RFI question categories in your comment, with emphasis on cash flow timing, rebate denial guardrails, and data requirements.
Contact your congressional representatives to support H.R. 7391 through NACHC and PACHC advocacy channels.
Audit your data pipeline — confirm EHR-to-pharmacy-to-340B eligibility field capture for rebate submission readiness.
Calendar the April 27, 2026 ICR deadline — HRSA’s separate Information Collection Request (Federal Register Document 2026-03833) has a distinct comment deadline one week after the RFI close.

Denial Prevention Takeaway

Revenue cycle leaders at FQHCs should treat the rebate model as an emerging denial management problem — not a pharmacy-only policy issue. The 45-day submission window is a timely filing rule. Rebate rejections are claim denials. Revenue leakage from missed or incomplete submissions is the same problem as uncaptured charges. The infrastructure needed to protect 340B recovery under a rebate model is identical to what protects clean claim submission: complete data capture, hard filing deadlines, accountable ownership, and escalation protocols. Start building it now — before HRSA finalizes a reconstituted pilot that may expand beyond the original nine drugs.

Identify exposure: Map all formulary drugs against pilot scope and IRA-negotiated drug lists; model WAC-to-ceiling cash flow gap at current dispense volumes.
Audit data readiness: Confirm that your EHR-to-pharmacy-to-340B eligibility pipeline captures all 12 to 14 required rebate claim fields automatically and accurately.
Submit by April 20: Your organization’s documented financial data is direct evidence for the safeguards HRSA must build into any reconstituted rule. Considering the court found HRSA failed to consider this data the first time, comment submissions from FQHCs carry weight.

Sources